Cannabis and neurodevelopment: Implications for psychiatric disorders

Human Psychopharmacology

Volumn 21, Issue 4, 2006, Pages 245-254

  Sundram, Suresh ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cannabis; Cognition; Major depression; Neurodevelopment; Schizophrenia; Substance use disorders

Indexed keywords

CANNABINOID; CANNABIS; DOPAMINE; NEUROTRANSMITTER; OPIATE; SEX HORMONE;

ANXIETY; BRAIN DEVELOPMENT; CANNABIS ADDICTION; CHILD PSYCHIATRY; COGNITION; COGNITIVE DEFECT; DEPRESSION; DEPTH PERCEPTION; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GENDER; HEREDITY; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MENTAL DISEASE; MOOD; MOTOR CONTROL; NEUROENDOCRINE SYSTEM; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; ONTOGENY; OUTCOMES RESEARCH; PERINATAL PERIOD; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE;

AFFECT; ANIMALS; ANXIETY; BRAIN; CANNABIS; COGNITION; ENDOCANNABINOIDS; FEMALE; FETUS; HUMANS; MENTAL DISORDERS; PREGNANCY;

EID: 33745905593     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.762     Document Type: Review

References (93)

1. Agrawal A, Neale MC, Prescott CA, Kendler KS. 2004. A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. Psychol Med 34: 1227-1237.
2. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. 2002. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325: 1212-1213.
3. Arseneault L, Cannon M, Witton J, Murray RM. 2004. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184: 110-117.
4. Australian Institute of Health and Welfare. 2005. Statistics on Drug Use in Australia 2004. Australian Institute of Health and Welfare: Canberra.
5. Baker D, Pryce G, Giovannoni G, Thompson AJ. 2003. The therapeutic potential of cannabis. Lancet Neurol 2: 291-298.
6. Behnke M, Eyler FD. 1993. The consequences of prenatal substance use for the developing fetus, newborn, and young child. Int J Addict 28: 1341-1391.
7. Berghuis P, Dobszay MB, Wang X., et al. 2005. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA 102: 19115-19120.
8. Biscaia M, Marin S, Fernandez B, et al. 2003. Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology (Berl) 170: 301-308.
9. Bonnin A, de Miguel R, Castro JG, Ramos JA, Fernandez-Ruiz JJ. 1996. Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase- containing neurons in rat brain. J Mol Neurosci 7: 291-308.
10. Buhler B, Hambrecht M, Loffler W, an der HW, Hafner H. 2002. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 54: 243-251.
11. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G. 2001. Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology (Berl) 158: 259-266.
12. Castle D, Murray R (eds). 2004. Marijuana and Madness. Cambridge University Press; Cambridge.
13. Chen K, Kandel DB. 1998. Predictors of cessation of marijuana use: an event history analysis. Drug Alcohol Depend 50: 109-121.
14. Day N, Sambamoorthi U, Taylor P, et al. 1991. Prenatal marijuana use and neonatal outcome. Neurotoxicol Teratol 13: 329-334.
15. Day N, Cornelius M, Goldschmidt L, Richardson G, Robles N, Taylor P. 1992. The effects of prenatal tobacco and marijuana use on offspring growth from birth through 3 years of age. Neurotoxicol Teratol 14: 407-414.
16. Day NL, Richardson GA, Goldschmidt L, et al. 1994. Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol 16: 169-175.
17. De Petrocellis L, Cascio MG, Di Marzo V. 2004. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141: 765-774.
18. Di Marzo V, Bifulco M, De Petrocellis L. 2004. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3: 771-784.
19. Ebrahim SH, Gfroerer J. 2003. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol 101: 374-379.
20. Fergusson DM, Horwood LJ. 1997. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 92: 279-296.
21. Fergusson DM, Horwood LJ, Northstone K. 2002a. Maternal use of cannabis and pregnancy outcome. BJOG 109: 21-27.
22. Fergusson DM, Horwood LJ, Swain-Campbell N. 2002b. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97: 1123-1135.
23. Fernandez-Ruiz JJ, Berrendero F, Hernandez ML, Romero J, Ramos JA. 1999. Role of endocannabinoids in brain development. Life Sci 65: 725-736.
24. Fernandez-Ruiz J, Gomez M, Hernandez M, de Miguel R, Ramos JA. 2004. Cannabinoids and gene expression during brain development. Neurotox Res 6: 389-401.
25. Fowler CJ. 2005. Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors. Curr Drug Targets CNS Neurol Disord 4: 685-696.
26. Fried PA. 2002. Conceptual issues in behavioral teratology and their application in determining long-term sequelae of prenatal marihuana exposure. J Child Psychol Psychiatry 43: 81-102.
27. Fried PA, Makin JE. 1987. Neonatal behavioural correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol Teratol 9: 1-7.
28. Fried PA, Smith AM. 2001. A literature review of the consequences of prenatal marihuana exposure: an emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol 23: 1-11.
29. Fried PA, Watkinson B. 1990. 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr 11: 49-58.
30. Fried PA, Buckingham M, Von Kulmiz P. 1983. Marijuana use during pregnancy and perinatal risk factors. Am J Obstet Gynecol 146: 992-994.
31. Fried PA, Watkinson B, Gray R. 1998. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 20: 293-306.
32. Fried P, Watkinson B, James D, Gray R. 2002. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ 166: 887-891.
33. Fried PA, Watkinson B, Gray R. 2003. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 25: 427-436.
34. Fried PA, Watkinson B, Gray R. 2005. Neurocognitive consequences of marihuana-a comparison with pre-drug performance. Neurotoxicol Teratol 27: 231-239.
35. Glass M, Dragunow M, Faull RL. 1997. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the foetal, neonatal and adult human brain. Neuroscience 77: 299-318.
36. Goldschmidt L, Day NL, Richardson GA. 2000. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol 22: 325-336.
37. Goldschmidt L, Richardson GA, Cornelius MD, Day NL. 2004. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol 26: 521-532.
38. Gray KA, Day NL, Leech S, Richardson GA. 2005. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol 27: 439-448.
39. Hall W, Christie M, Currow D. 2005. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6: 35-42.
40. Herkenham M, Lynn AB, Little MD, et al. 1990. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 1932-1936.
41. Hingson R, Alpert JJ, Day N, et al. 1982. Effects of maternal drinking and marijuana use on fetal growth and development. Pediatrics 70: 539-546.
42. Howlett AC, Barth F, Bonner TI, et al. 2002. International Union of Pharmacology, XXVII: classification of Cannabinoid Receptors. Pharmacol Rev 54: 161-201
43. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. 2004. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 (Suppl. 1): 345-358.
44. Kumar AM, Haney M, Becker T, Thompson ML, Kream RM, Miczek K. 1990. Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain. Brain Res 525: 78-83.
45. Lamarque S, Taghzouti K, Simon H. 2001. Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 41: 118-129.
46. Levitt P, Harvey JA, Friedman E, Simansky K, Murphy EH. 1997. New evidence for neurotransmitter influences on brain development. Trends Neurosci 20: 269-274.
47. Lynskey MT, Heath AC, Bucholz KK, et al. 2003. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 289: 427-433.
48. Macri S, Laviola G. 2004. Single episode of maternal deprivation and adult depressive profile in mice: interaction with cannabinoid exposure during adolescence. Behav Brain Res 154: 231-238.
49. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. 1999. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20: 287-294.
50. Mechoulam R, Hanus L. 2000. A historical overview of chemical research on cannabinoids. Chem Phys Lipids 108: 1-13.
51. Molina-Holgado F, Amaro A, Gonzalez MI, Alvarez FJ, Leret ML. 1996. Effect of maternal delta 9-tetrahydrocannabinol on developing serotonergic system. Eur J Pharmacol 316: 39-42.
52. Molina-Holgado F, Alvarez FJ, Gonzalez I, Antonio MT, Leret ML. 1997. Maternal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) alters indolamine levels and turnover in adult male and female rat brain regions. Brain Res Bull 43: 173-178.
53. Moreno M, Trigo JM, Escuredo L, Rodriguez de Fonseca F, Navarro M. 2003. Perinatal exposure to delta 9-tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: a behavioral study in rats. Pharmacol Biochem Behav 75: 565-575.
54. O'Shea M, Singh ME, McGregor IS, Mallet PE. 2004. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 18: 502-508.
55. Ostrea EMJr., Brady M, Gause S, Raymundo AL, Stevens M. 1992. Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics 89: 107-113.
56. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. 2002. Cannabis use and mental health in young people: cobort study. BMJ 325: 1195-1198.
57. Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M. 2005. Reverse gateways?: frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100: 1518-1525.
58. Perez-Rosado A, Manzanares J, Fernandez-Ruiz J, Ramos JA. 2000. Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences. Brain Res Dev Brain Res 120: 77-81.
59. Perez-Rosado A, Gomez M, Manzanares J, Ramos JA, Fernandez-Ruiz J. 2002. Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Delta(9)-tetrahydrocannabinol. Neurotox Res 4: 211-218.
60. Piomelli D. 2003. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
61. Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL. 2004. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 56: 86-94.
62. Pope HGJr., Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. 2003. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 69: 303-310.
63. Porath AJ, Fried PA. 2005. Effects of prenatal cigarette and marijuana exposure on drug use among offspring. Neurotoxicol Teratol 27: 267-277.
64. Pryce G, Baker D. 2005. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci 28: 272-276.
65. Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey M. 2002. Mental health of teenagers who use cannabis: results of an Australian survey. Br J Psychiatry 180: 216-221.
66. Richardson GA, Day NL, Goldschmidt L. 1995. Prenatal alcohol, marijuana, and tobacco use: infant mental and motor development. Neurotoxicol Teratol 17: 479-487.
67. Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. 2002. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol 24: 309-320.
68. Rubio P, Rodriguez de Fonseca F, Martin-Calderon JL, et al. 1998. Maternal exposure to low doses of delta9-tetrahydrocannabinol facilitates morphine-induced place conditioning in adult male offspring. Pharmacol Biochem Behav 61: 229-238.
69. Schlicker E, Kathmann M. 2001. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 565-572.
70. Schneider M, Koch M. 2003. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28: 1760-1769.
71. Schneider M, Drews E, Koch M. 2005. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2. Behav Pharmacol 16: 447-454.
72. Solowij N. 1998. Cannabis and Cognitive Functioning. Cambridge University Press: Cambridge.
73. Solowij N, Stephens RS, Roffman RA, et al. 2002. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287: 1123-1131.
74. Spencer GE, Klumperman J, Syed NI. 1998. Neurotransmitters and neurodevelopment: role of dopamine in neurite outgrowth, target selection and specific synapse formation. Perspect Dev Neurobiol 5: 451-467.
75. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. 2004. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 99: 1333-1341.
76. Suarez I, Bodega G, Fernandez-Ruiz J, Ramos JA, Rubio M, Fernandez B, 2004a. Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal delta9-tetrahydrocannabinol exposure. Cerebellum 3: 66-74.
77. Suarez I, Bodega G, Rubio M, Fernandez-Ruiz JJ, Ramos JA, Fernandez B. 2004b. Prenatal cannabinoid exposure down-regulates glutamate transporter expressions (GLAST and EAAC1) in the rat cerebellum. Dev Neurosci 26: 45-53.
78. Substance Abuse and Mental Health Services Administration. 2004. Results from the 2003 national survey on drug use and health: national findings. Rockville. Substance Abuse and Mental Health Services Administration.
79. Tanda G, Pontieri FE, Di Chiara G. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050.
80. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. 1998. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411.
81. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM. 1999. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurans in the rat hippocampal formation. Neuroscience 93: 969-975.
82. van der Stelt M, Di Marzo V. 2005. Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med 7: 37-50.
83. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. 2002. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156: 319-327.
84. Van Sickle MD, Duncan M, Kingsley PJ, et al. 2005. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.
85. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. 2004. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 161: 501-506.
86. Vela G, Fuentes JA, Bonnin A, Fernandez-Ruiz J, Ruiz-Gayo M. 1995. Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats. Brain Res 680: 142-147.
87. Vela G, Martin S, Garcia-Gil L, et al. 1998. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res 807: 101-109.
88. Viveros MP, Llorente R, Moreno E, Marco EM. 2005. Behavioural and neuroendocrine effects of cannabinoids in critical developmental periods. Behav Pharmacol 16: 353-362.
89. Wang X, Dow-Edwards D, Keller E, Hurd YL. 2003. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 118: 681-694.
90. Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL. 2004. In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry 56: 909-915.
91. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. 1994. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63: 637-652.
92. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. 2002. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325: 1199.
93. Zuckerman B, Frank DA, Hingson R, et al. 1989. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 320: 762-768.